193 related articles for article (PubMed ID: 32890995)
21. Ligand-based autotaxin pharmacophore models reflect structure-based docking results.
Mize CD; Abbott AM; Gacasan SB; Parrill AL; Baker DL
J Mol Graph Model; 2011 Nov; 31():76-86. PubMed ID: 21967734
[TBL] [Abstract][Full Text] [Related]
22. A defective lysophosphatidic acid-autophagy axis increases miscarriage risk by restricting decidual macrophage residence.
Yang HL; Lai ZZ; Shi JW; Zhou WJ; Mei J; Ye JF; Zhang T; Wang J; Zhao JY; Li DJ; Li MQ
Autophagy; 2022 Oct; 18(10):2459-2480. PubMed ID: 35220880
[TBL] [Abstract][Full Text] [Related]
23. Exosomes bind to autotaxin and act as a physiological delivery mechanism to stimulate LPA receptor signalling in cells.
Jethwa SA; Leah EJ; Zhang Q; Bright NA; Oxley D; Bootman MD; Rudge SA; Wakelam MJ
J Cell Sci; 2016 Oct; 129(20):3948-3957. PubMed ID: 27557622
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent inhibitors of the lysophospholipase autotaxin.
Shah P; Cheasty A; Foxton C; Raynham T; Farooq M; Gutierrez IF; Lejeune A; Pritchard M; Turnbull A; Pang L; Owen P; Boyd S; Stowell A; Jordan A; Hamilton NM; Hitchin JR; Stockley M; MacDonald E; Quesada MJ; Trivier E; Skeete J; Ovaa H; Moolenaar WH; Ryder H
Bioorg Med Chem Lett; 2016 Nov; 26(22):5403-5410. PubMed ID: 27780639
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
26. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8
Matas-Rico E; Frijlink E; van der Haar Àvila I; Menegakis A; van Zon M; Morris AJ; Koster J; Salgado-Polo F; de Kivit S; Lança T; Mazzocca A; Johnson Z; Haanen J; Schumacher TN; Perrakis A; Verbrugge I; van den Berg JH; Borst J; Moolenaar WH
Cell Rep; 2021 Nov; 37(7):110013. PubMed ID: 34788605
[TBL] [Abstract][Full Text] [Related]
27. Autotaxin-LPA axis regulates hMSC migration by adherent junction disruption and cytoskeletal rearrangement via LPAR1/3-dependent PKC/GSK3β/β-catenin and PKC/Rho GTPase pathways.
Ryu JM; Han HJ
Stem Cells; 2015 Mar; 33(3):819-32. PubMed ID: 25376707
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
Durgam GG; Virag T; Walker MD; Tsukahara R; Yasuda S; Liliom K; van Meeteren LA; Moolenaar WH; Wilke N; Siess W; Tigyi G; Miller DD
J Med Chem; 2005 Jul; 48(15):4919-30. PubMed ID: 16033271
[TBL] [Abstract][Full Text] [Related]
29. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
30. Structural Basis for Inhibition of Human Autotaxin by Four Potent Compounds with Distinct Modes of Binding.
Stein AJ; Bain G; Prodanovich P; Santini AM; Darlington J; Stelzer NM; Sidhu RS; Schaub J; Goulet L; Lonergan D; Calderon I; Evans JF; Hutchinson JH
Mol Pharmacol; 2015 Dec; 88(6):982-92. PubMed ID: 26371182
[TBL] [Abstract][Full Text] [Related]
31. Biological roles of lysophosphatidic acid signaling through its production by autotaxin.
Okudaira S; Yukiura H; Aoki J
Biochimie; 2010 Jun; 92(6):698-706. PubMed ID: 20417246
[TBL] [Abstract][Full Text] [Related]
32. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
33. Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish.
Lai SL; Yao WL; Tsao KC; Houben AJ; Albers HM; Ovaa H; Moolenaar WH; Lee SJ
Development; 2012 Dec; 139(23):4439-48. PubMed ID: 23095890
[TBL] [Abstract][Full Text] [Related]
34. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
35. Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish.
Yukiura H; Hama K; Nakanaga K; Tanaka M; Asaoka Y; Okudaira S; Arima N; Inoue A; Hashimoto T; Arai H; Kawahara A; Nishina H; Aoki J
J Biol Chem; 2011 Dec; 286(51):43972-43983. PubMed ID: 21971049
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
[TBL] [Abstract][Full Text] [Related]
37. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD
J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925
[TBL] [Abstract][Full Text] [Related]
38. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
[TBL] [Abstract][Full Text] [Related]
39. Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.
Tigyi GJ; Yue J; Norman DD; Szabo E; Balogh A; Balazs L; Zhao G; Lee SC
Adv Biol Regul; 2019 Jan; 71():183-193. PubMed ID: 30243984
[TBL] [Abstract][Full Text] [Related]
40. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
